ABBN.SW: $85.88 ▼ -0.22 (-0.26%)ASML.AS: $1,565.20 ▲ 4.40 (0.28%)ENR.DE: $161.54 ▼ -0.96 (-0.59%)GLEN.L: $537.60 ▲ 2.30 (0.43%)IFX.DE: $80.97 ▲ 0.41 (0.51%)NOKIA.HE: $12.16 ▲ 0.16 (1.33%)RIO.L: $7,295.00 ▲ 31.00 (0.43%)AMD: $519.85 ▼ -31.78 (-5.76%)INTC: $132.28 ▼ -8.66 (-6.14%)MU: $1,051.77 ▼ -159.61 (-13.18%)WDC: $670.75 ▼ -61.87 (-8.45%)AAPL: $294.30 ▼ -2.71 (-0.91%)AMZN: $234.11 ▲ 1.32 (0.57%)NVDA: $200.04 ▼ -8.61 (-4.13%)AMAT: $585.88 ▼ -54.30 (-8.48%)CIEN: $459.85 ▼ -0.48 (-0.10%)STX: $1,038.59 ▼ -55.45 (-5.07%)

Company Details

Enanta Pharmaceuticals, Inc.

ENTA - NASDAQ

Identifiants & Marche

Ticker ENTA
ISIN US29251M1062
CIK 0001177648
Bourse NASDAQ
Devise USD

Classification

Secteur Healthcare
Industrie Biotechnology

Entreprise

Pays US
Siege N/A
Fondee N/A
Site Web Lien

Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.